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by
VICTOR CHUKWU
(Under the Direction of Karl Peace)
ABSTRACT
In Clinical Practice, combination drug therapy has become common in treating many disease
conditions. The purpose of these combinations is often to ensure optimal efficacy and to reduce
adverse effects that may arise from monotherapy. Clinical trials have also been conducted to
ensure efficacy and safety of these combinations before they are introduced into the market.
However, adverse effects still occur with combination therapies. The objective of this study is to
(1) To determine a region of optimum doses of Drug A and Drug B in combination while
focusing on efficacy alone (2) To determine a region of optimum doses of Drug A and Drug B
while focusing on efficacy incorporating important safety constraints. Using Hypertension as the
disease of interest, the primary efficacy endpoint is the change in diastolic blood pressure from
baseline to the end of treatment at 8 weeks, and the adverse effect is edema. Drug A in doses of
0mg, 2.5mg, 5mg, 10mg and Drug B in doses of 0mg, 20mg, 40mg, 80mg were used in
combination in the treatment of hypertension I and II. Response Surface Methodology (RSM)
was used to find the doses of Drug A and Drug B which maximized efficacy, and a ProbitNormal Model was used to model the probability of the occurrence of edema. Results showed an
unconstrained optimal decrease of 21mmhg corresponding to 12mg of A and 48mg of B. The
point of minimum risk of the probability of edema occurring coincided with 2.5mg of Drug A
and 20mg of Drug B (0.006%). The region of minimal edema incidence lay around the

combination of 2.5mg of Drug A and 20-40mg of Drug B. A combination of 10mg of Drug A
and no dose of Drug B showed the highest probability of edema. At a desired target of zero
probability of edema occurrence, the constrained optimal value was about 15mmhg. Response
Surface Methodology (RSM) has been applied in many disciplines; constraint optimization
methods are relatively novel in their application to health and clinical dosing. Application of this
method will require formulation of constraints that are appropriate for the disease of interest, and
that is also clinically appropriate.
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CHAPTER 1
INTRODUCTION
A Clinical trial is a research study conducted to assess the utility of an intervention.
Interventions can be biologics, drugs or devices, and can be preventive, diagnostic or therapeutic
(Peace & Chen, 2010).
Clinical trials are conducted in different phases; (i) human pharmacology study, (ii)
therapeutic exploratory study (iii) therapeutic confirmatory study (iv) therapeutic use study or
post marketing surveillance study (ICH, 1997). These are commonly known as Phase I, Phase II,
Phase III and Phase IV, respectively. Though the objectives of each phase are clear, the
processes during each phase are not restrictive. Phase I trials are usually conducted in healthy
subjects. This phase identifies the safety range, a range of tolerable doses to avoid future severe
adverse effects (Peace & Chen, 2010). The major objective is to estimate the “maximum dose
level” – Maximum Tolerated dose (MTD) – “that is acceptable for a patient or participant
without causing unacceptable toxicity” (Hee, 2012). This phase also assesses the absorption,
distribution, metabolism and excretion of drugs. In cancer, “Virtually all existing phase I designs
rely on toxicity while making the implicit assumption that higher doses are associated with
higher response rates” (Thall & Russell, 1998).
Phase II and III clinical trials are controlled. The effects of an experimental treatment and
a control treatment are compared. The control treatment could be a placebo, or an “existing
established effective treatment” (Fitzpatrick, 2005). Phase II clinical trials estimate the dose and
frequency of dosing needed for designing the pivotal proof of efficacy trials. Phase II trials focus
on the efficacy of the drug but are not usually designed with large power. Several dose levels and

8
frequencies of dosing of the new treatment are compared to a control or a known standard
treatment. Phase III clinical trials are designed with large power to confirm the efficacy of the
treatment regimen determined in Phase II (Peace & Chen, 2010). Phase III trials are normally
conducted in many centers (multi-center trials), due to the requirement of large sample sizes. In
addition to confirmation of efficacy, many Phase III trials collect longer term safety data (Peace
& Chen, 2010). Phase IV clinical trials are conducted after the drug has been approved and
registered and aim to assess safety and collect efficacy data in a more heterogeneous population.
Hypertension
Hypertension is an increase in blood pressure above normal levels. It affects about 75
million Americans (32%), and only about half (54%) of those with this condition have it under
control (CDC, 2016). The prevalence of hypertension has remained significantly unchanged
despite the availability of numerous antihypertensive drugs. Hypertension is a risk factor for
many cardiovascular diseases such as stroke, peripheral arterial disease, renal insufficiency, atrial
fibrillation and dementia (Alberto Francisco, 2018). Several studies have shown that combined
therapy is more effective in the treatment of hypertension. Combined therapy is advised for
patients whose systolic pressure is 20mmHg above the target or diastolic pressure is 10mmHg
above the target (Alberto Francisco, 2018). It has been demonstrated that combination therapy:
(i) lowers the blood pressure more rapidly, (ii) encourages better adherence, (iii) has been
associated with better control of the blood pressure due to less titration of monotherapy and is
(iv) less associated with adverse effects. There is ample evidence to show that outcomes are
better with combined therapy (Ahc, 2019). Though the use of combination therapy protects
target organs against high dosage damages in monotherapy (Alberto Francisco, 2018), it is
important to note that safety always places a constraint on efficacy (Peace & Chen, 2010). Drug

9
treatments are not always without side effects even with combination therapy. There is a risk for
potential drug toxicity as the doses are increased to control blood pressure. In a recently
concluded clinical trial, the combination of telmisartan and Ramipril have decreased glomerular
filtration rate, increased serum creatinine and the risk of dialysis (Alberto Francisco, 2018).
Research Objectives
This research focuses on determining a region of doses of two drugs to be used in
combination over which the efficacy of the combination is optimal (in some clinical sense) while
constraining for safety (comparative effect of combination to control at an acceptable clinical
level) in hypertensive patients. This may provide an alternative way to determine the dose levels
for fixed combination drugs that may prove effective and safer in patients who require a fixed
dose drug combination to treat their hypertension. Defining a region of efficacy while
constraining for safety may lead to a reduction in side effects while successfully treating patients.
Results from this research may enhance the establishment of a template where the method can be
applied to a fixed dose combination in the treatment of other diseases. Our aim is:
(1)

To illustrate determining a region of optimum doses of two drugs given in combination

while focusing on efficacy alone, (RE)
(2) To illustrate determining a region of optimum doses of two drugs while focusing on efficacy
and incorporating an important safety constraint (RE|s).
Possible Research Outcomes
(1) RE|s is a subset of RE; This will be a positive result, as the region of efficacy constraining for
safety has been defined and can be used for further consideration and studies.
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(2) RE|s does not overlap with RE; then the efficacy of combination will need to be re-evaluated.
It may be that RE is a subset of RE|s. In this case, the method may need to be re-evaluated, or
deemed not suitable.
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CHAPTER 2
LITERATURE REVIEW
The maximum tolerated dose (MTD) is the highest dose with a clinically acceptable level
of toxicity (Kong, Rai, & Bolli, 2014). Researchers have used various methods to find the dose
of a treatment that meets both safety and efficacy requirements. This research proposes using
response surface methods to simultaneously optimize the dose of a drug treatment, in the
presence of safety constraints (adverse effects).
Adverse Effects in Drug Therapy
An adverse effect or reaction is “an appreciably harmful or unpleasant reaction, resulting
from an intervention related to the use of a medicinal product, which predicts hazard from future
administration and warrants prevention or specific treatment, or alteration of the dosage regimen,
or withdrawal of the product” (Edwards & Aronson, 2000). These reactions can be classified into
six types; Dose-related, non – dose related, dose – related and time – related, time – related,
withdrawal and failure of therapy (Edwards & Aronson, 2000). Some of these effects can be
unexpected, in which case not “consistent with domestic labelling” or expected from the known
attributes of the drug. They could just be manifested during therapy without any causal link to
the treatment, or could be serious, requiring hospital admission, prolonged hospital stay and
resulting into disability or death (Edwards & Aronson, 2000). “Several studies carried out in the
US have investigated adverse drug effects experienced by hospitalized patients and their impact
on hospital costs. Patients who developed adverse effects were hospitalized an average of 1.2–
3.8 days longer than patients who did not, with additional hospital costs of $US2284–5640 per
patient (2000 values)” (Rodríguez-Monguió, Otero, & Rovira, 2003).
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Antihypertensives and Adverse Effects
Croog et al conducted a multicenter randomized double-blind clinical trial among
patients with hypertension. They showed that antihypertensive agents have several effects on the
quality of life (Croog et al., 1986). A long-term surveillance study by Curb et al among
hypertensive patients showed that 23.4% had “drug treatment discontinued due to possible side
effects,” although only 1% of active participants required hospitalization (Curb et al., 1985).
Table 1: Profile of Antihypertensives and Adverse Effects
Class

Examples

Mechanism of Action

Common Adverse Effects

Alpha Blockers

Terazosin, Doxazosin

Blocks binding to alpha

Fatigue, Dizziness, Weight

receptors to prevent

gain, hypotension, slow

contraction and

heart rate, shortness of

narrowing of blood

breath

vessels
Angiotensin –

Captopril, Lisinopril,

Reduces blood pressure

Fatigue, Headache, Cough,

Converting

Perindopril, Ramipril,

by inhibiting

Hypotension, Increase in

Enzyme Inhibitors

Benazepril

angiotensin (hormone)

potassium blood levels

(ACEIs)

hydrochloride, Moexipril

and preventing

etc.

vasoconstriction.

Angiotensin II

Azilsartan, Candesartan,

Prevents angiotensin

Diarrhea, Cough,

Receptor Blockers

Losartan, Telmisartan,

from binding to their

hypotension, Fatigue,

(ARBs)

Valsartan, Olmesartan

receptors, thereby

Headache, Indigestion, etc.

preventing
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vasoconstriction
Beta – Blockers

Atenolol, Carvedilol,

Reduces heart rate, and

Fatigue, Dizziness,

Labetalol, Metoprolol,

force of pressure,

Impotence, hypotension,

Nadolol, Bisoprolol etc.

reduces blood volume

shortness of breath, etc.

Calcium channel

Amlodipine, Felodipine,

Reduces muscular

Edema, Rash, Headache,

blockers

Nifedipine, Nimodipine,

contractions in the heart

Constipation, Shortness of

Nicardipine, Verapamil,

by blocking the influx of breath etc.

Clevidipine etc.

calcium

Centrally acting

Clonidine,

Works on the central

Low blood pressure,

drugs

Hydrochloride,

nervous system to

Withdrawal symptoms,

Guanfacine

reduce blood pressure

Drowsiness, Headache etc.

Chlorothiazide,

Lowers blood volume,

Dehydration, Hypotension,

Ethacrynate,

increases urination,

Fatigue, hyperglycemia,

Bumetanide, Furosemide

reduces sodium

increase level of uric acid.

hydrochloride
Diuretics

etc.
Renin Inhibitors

Aliskiren

Etc.
Inhibits the conversion

Diarrhea, Increased

of angiotensinogen to

potassium blood levels, etc.

angiotensin I
Vasodilators

Minoxidill, Hydralazine

Causes vasodilation of

Edema, Weight gain,

blood vessels thereby

Increased heart rate,

reducing blood pressure

Headache etc.

14
Dosage Optimization in Combination Therapy
Hatala et al, in a prospective, real-life, open-label, longitudinal, phase IV study optimized
the treatment of blood pressure in patients with arterial hypertension with fixed-combination
dosage of Perindopril/Amlodipine. Results showed marked reduction in systolic and diastolic
blood pressure with reports of several side effects, the commonest of which was edema.
However, there was notable reduction in the incidence of edema from 15% in patients treated
with amlodipine at baseline to 7.9% after 1 months, and 6.3% after 3 months in patients treated
with perindopril and amlodipine (Hatala, Pella, Hatalová, & Šidlo, 2012). Chen et al using
pharmacokinetics/pharmacodynamic analysis and Monte-Carlo simulations optimized the dosage
regimen of voriconazole to improve the efficacy in patients with invasive fungal disease (Chen et
al., 2016). Optimization of Rituximab dosage in patients with non-Hodgkin’s lymphoma was
found to be beneficial, using a validated pharmacokinetic/pharmacodynamic model but has yet to
be confirmed in clinical trials (Ternant et al., 2012). Thall & Russell (1998) designed a single
arm phase I/II trial, which included “dose-finding and simultaneous evaluation of safety and
efficacy” (Thall & Russell, 1998). They were interested in generating decision rules using
Bayesian criteria, calibrate the design parameters, and repeat the process until good operating
characteristics were obtained (Thall & Russell, 1998).
Constraint optimization of dosage in therapy may prevent suboptimal dosing in the
treatment of serious health conditions. Physicians are careful in increasing doses among those
with serious health conditions to avoid life threatening side effects. According to Niriayo et al,
“medical practitioners may fail to prescribe high dose of Angiotensin Converting Enzyme
Inhibitors (ACEIs) for older patients due to fear of intolerance,” and suboptimal dosage of
ACEIs in patients with heart failure have resulted in increase in hospitalization (Niriayo,
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Kumela, Gidey, & Angamo, 2019). In a cross-sectional study, binary logistic regression analysis
was conducted to identify factors that affect utilization and optimal dosing of ACEIs (Niriayo et
al., 2019). Optimizing ACEIs dosage in heart failure patients have proven to be have a better
treatment outcome. “Evidence- based guidelines have recommended up titration of ACEIs to a
target dose unless there is tolerability problem” (Niriayo et al., 2019). Further studies with
constraint optimization will encourage adequate dosing in patients with less concerns over the
side effects.
Methods for Optimization
“The problem of optimizing a quadratic primary-response function in the presence of a
quadratic secondary-response function was considered by Myers and Carter” (1973). “ They also
showed a special case of ridge analysis” (Stablein, Carter, & Wampler, 1983). Kong et al
provided statistical methods for selecting the maximum effective dose and evaluating treatment
effect when dose – response is monotonic (Kong et al., 2014). The methods proposed for a
single-stage design and one two-stage design, require a prior assumption of a monotonic doseresponse and a tested non-toxic dose range (Kong et al., 2014). Optimizing an optimal design
with these methods can be “challenging yet interesting” (Kong et al., 2014).
This research will use Response Surface Methodology (RSM) to find the optimum region
of efficacy of Drug A and Drug B while simultaneously constraining for safety. Response
surface models are general linear models in which attention focuses on characteristics of the
fitted response function and in particular, where optimum estimated response values occur (SAS,
2019). Response surface analysis is often “centered on the estimation of the levels of the design
variables associated with the optimum response” (Stablein et al., 1983). “Response surface
methodology is a kind of effective method to optimize process conditions, and it can determine
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the influence of various factors and their interactions on the indices under investigation (response
value) during technological operation. It can be used to fit a complete quadratic polynomial
model through central composite experiment, and present more excellent experimental design
and results expression” (H.Liu, 2016). RSM can also be used to generate “predicted values of
changes from baseline for dose combinations not in the design” (H.Liu, 2016). It can also be
used to study the additive property of combination drugs, and the “nature of the dose response”
(H.Liu, 2016).
Constrained optimization has been applied in different areas ranging from mathematics,
computer science, engineering and economics (Crown et al., 2017). “With advances in
computing technology, constrained optimization methods designed to handle broader range of
problems trace their origin to the development of the simplex algorithm – the most commonly
used algorithm to solve linear constrained optimization problems” (Crown et al., 2017). It can
also be useful in making clinical practice decisions where health professionals are faced with
constraints such as proximity to treatment centers, health insurance benefits designs, and limited
availability of health resources” (Crown et al., 2017). “These methods have been applied to
disease diagnosis, development of optimal treatment algorithms, and the optimal design of
clinical trials (Crown et al., 2017). There are various mathematical ways for solving
maximization with constraints problems. These include the direct solution method, graphical
method and the standard LaGrange multiplier method (Pernice, 2018). The LaGrange multiplier
method, which was invented by an Italian mathematician Joseph-Louis LaGrange, is preferred
more so than other methods because it can be generalized easily to many dimensions and many
constraints (Pernice, 2018). “The method of Lagrange multipliers is used to solve constrained
minimization problems of the following form: minimize Φ(x) subject to the constraint C(x) = 0”
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(Menke & Menke, 2016). It should be noted that the method of maximum likelihood estimation
usually minimizes the negative log likelihood. “The Lagrange multipliers indicate how much the
value of the objective function at the optimal point will change for a small change in the right
hand side of the constraint” (S.K.Jain & Singh, 2007). In ridge analysis, “Inserting values λ
larger than the largest eigenvalue of the matrix B will result in a solution for the maximum
response on the radius R. And inserting values of λ smaller than the smallest eigenvalue of the
matrix B will result in a solution for the minimum response on the radius R” (Lawson, 2010).
Myers and Carter (1973) advised on how to choose λ to ensure an “absolute optimum as opposed
to a local one” (Stablein et al., 1983).
Confidence Optimum region
A confidence interval 100(1 − α)% can be constructed for the constrained optimum

operating conditions for fixed λ. Computation of confidence regions for the maximum points is
necessary to address sampling error problem (Del Castillo, 1996).
According to Stablein et al., 1983, “it is more convenient to fix the value of each of the

LaGrange multipliers, find the location of the constrained optimum, and then evaluate the
constraints functions at the location of the optimum. If all of the constraints on the solution are
satisfied then the solution is used. If not, the process is repeated with different values of the
LaGrange multiplier until an acceptable solution is found”. But this assumes that there is no
closed form solution for the LaGrange multiplier. A better approach would be to apply the
Karush-Kuhn-Tucker (KKT) method, where the LaGrange multplier can be obtained by fulfilling
the necessary conditions for optimality (Del Castillo, 1996).
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In a rotatable experimental design, (that is, the distance from the center to all points have
equal prediction variance) and the 𝑉𝑉𝑉𝑉𝑉𝑉(𝑦𝑦�(𝑥𝑥)) is the only function of the distance between x and

the center of the design region, √𝐱𝐱′𝐱𝐱, then we can find the stationary point using the Lagrangian
function:

𝐿𝐿 = 𝑏𝑏0 + 𝐱𝐱 ′ 𝐛𝐛 +

1
2

𝐱𝐱 ′ 𝐁𝐁𝐱𝐱 − 𝜇𝜇(x ′ x − 𝜌𝜌2 )

(1)

Where 𝜌𝜌 represents the radius of the experimental region, and 𝜇𝜇 is a Lagrange multiplier (Del
Castillo, 1996). The KKT conditions would require that we maximize equation (1), subject to:
𝜇𝜇 (x ′ x − 𝜌𝜌2 ) = 0

𝜹𝜹 = 𝐛𝐛 + 𝐁𝐁𝐁𝐁 − 𝟐𝟐𝟐𝟐𝟐𝟐 = 0
𝜇𝜇 ≥ 0

(𝑎𝑎)

(b)

(c)

Which produces x0 and the optimal value of 𝜇𝜇. Equation (a), (b) and (c) correspond to the KKT

necessary conditions for optimality.

According to Box and Hunter(1954), the “confidence region for a stationary point in the
unconstrained case” is given by 𝜹𝜹′ 𝐕𝐕 −𝟏𝟏 𝜹𝜹 ≤ 𝑠𝑠 2 𝑘𝑘𝐹𝐹𝛼𝛼,𝑘𝑘,𝑛𝑛−𝑝𝑝 where 𝐕𝐕 −𝟏𝟏 =

𝑬𝑬�𝜹𝜹𝜹𝜹′ �
𝝈𝝈𝟐𝟐

, s2 is the variance

estimate based on n-p degrees of freedom, n denotes the number of experimental points, and p

denotes the number of parameters. Box and Hunter (1957) also noted that the inequalty can be
reduced to:
𝜹𝜹′ 𝐕𝐕 −𝟏𝟏 𝜹𝜹 =

𝑛𝑛
𝜹𝜹′𝜹𝜹
𝑐𝑐𝑐𝑐
�
−
(𝛿𝛿 ′ 𝑥𝑥)2 � ≤ 𝒌𝒌𝒔𝒔𝟐𝟐 𝐹𝐹𝛼𝛼,𝑘𝑘,𝑛𝑛−𝑝𝑝
−1
2
−1
1 + 𝜆𝜆 𝑐𝑐𝜌𝜌 𝑐𝑐
1 + (𝜆𝜆 + 𝑙𝑙)𝑐𝑐𝜌𝜌2

(2)
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Where 𝑐𝑐 =

𝑛𝑛

𝐹𝐹+2√𝐹𝐹

, F represents the number of factorial points, 𝑙𝑙 =

𝑘𝑘(𝝀𝝀−𝟏𝟏)+𝟐𝟐

𝝀𝝀�(𝑲𝑲+𝟏𝟏)𝝀𝝀−𝒌𝒌�

and 𝜆𝜆 are the

design parameters used to assess rotatablity. The confidence region is derived by substituing for

𝜹𝜹 in equation (2). Any point that satisfies the equation (2) is inside the 100(1 − 𝛼𝛼 )% confidence

region for the constrained maximum point of the fitted response (Del Castillo, 1996).
Dual Surface Response Approach

This approach was first proposed by Myers and Carter in 1973, and was later developed
by Vining and Myers in 1990 for two responses that can be categorized as primary and
secondary responses (Lin & Tu, 1995). In this approach, second order models are fit to both a
primary and secondary responses, and then an optimization of the primary response will be done
subject to the secondary response.
Following the notations Vining and Myers used the primary and secondary responses
(respectively) can be written as:
𝑘𝑘

𝜂𝜂𝑐𝑐 = 𝛽𝛽0 + � 𝐵𝐵𝑖𝑖 𝑥𝑥𝑖𝑖 +
𝑖𝑖=1

𝑘𝑘

� 𝐵𝐵𝑖𝑖𝑖𝑖 𝑥𝑥𝑖𝑖 2𝑖𝑖
𝑖𝑖=1

𝑘𝑘

+ � � 𝛽𝛽𝑖𝑖𝑖𝑖 𝑥𝑥𝑖𝑖 𝑥𝑥𝑗𝑗 + 𝜀𝜀𝑐𝑐
𝑖𝑖<𝑗𝑗

𝑘𝑘

𝑘𝑘

𝑘𝑘

𝑖𝑖=1

𝑖𝑖=1

𝑖𝑖<𝑗𝑗

𝜂𝜂𝑝𝑝 = 𝛾𝛾0 + � 𝛾𝛾𝑖𝑖 𝑥𝑥𝑖𝑖 + � 𝛾𝛾𝑖𝑖𝑖𝑖 𝑥𝑥𝑖𝑖2 + � � 𝛾𝛾𝑖𝑖𝑖𝑖 𝑥𝑥𝑖𝑖 𝑥𝑥𝑗𝑗 + 𝜀𝜀𝑝𝑝
And the fitted response surfaces resulting from the equations above can be represented by:
𝑤𝑤
�𝑐𝑐 = 𝑏𝑏0 + 𝐱𝐱 ′ 𝐛𝐛 + 𝐱𝐱′𝐁𝐁𝐁𝐁
𝑤𝑤
�𝑝𝑝 = 𝑐𝑐0 + 𝐱𝐱 ′ 𝐜𝐜 + 𝐱𝐱′𝐂𝐂𝐂𝐂

′
where 𝑏𝑏0 = 𝛽𝛽̂0 , 𝑐𝑐0 = 𝛾𝛾�0 , 𝐛𝐛 = �𝛽𝛽̂1 , … , 𝛽𝛽̂𝑘𝑘 � , 𝐜𝐜 = (𝛾𝛾�1 , … , 𝛾𝛾�𝑘𝑘 )′ ,
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2𝛽𝛽̂
⎡ 11
1 ̂
𝐁𝐁 = ⎢ 𝛽𝛽12
2⎢ ⋮
⎣ 𝛽𝛽̂1𝑘𝑘
2𝛾𝛾11
�
1 𝛾𝛾
𝐂𝐂 = � 12
2
⋮
𝛾𝛾�1𝑘𝑘

𝛽𝛽̂12
2𝛽𝛽̂22
…
̂
𝛽𝛽2𝑘𝑘
𝛾𝛾�12
2𝛾𝛾�22
…
𝛾𝛾�2𝑘𝑘

…
⋯
⋱
⋯
…
⋯
⋱
⋯

𝛽𝛽̂1𝑘𝑘
⎤
𝛽𝛽̂2𝑘𝑘 ⎥
⋮ ⎥
̂
2𝛽𝛽𝑘𝑘𝑘𝑘 ⎦
𝛾𝛾�1𝑘𝑘
𝛾𝛾�2𝑘𝑘
�
⋮
2𝛾𝛾�𝑘𝑘𝑘𝑘

Where 𝑏𝑏0 , 𝑐𝑐0 , 𝐛𝐛, 𝐜𝐜, 𝐁𝐁, and 𝐂𝐂 are the appropriate vectors and matrices of the estimates for the
coefficients.

Vining and Myers proposed a method using LaGrange multipliers, for finding x that
optimizes 𝑤𝑤
�𝑐𝑐 subject to 𝑤𝑤
�𝑝𝑝 = T, “where T is some desired target value of the constraint response

and a spherical region of interest is assumed” (2). The goal is to find x that satisfies:
𝜕𝜕𝜕𝜕
=0
𝜕𝜕𝐱𝐱

Where,

𝐿𝐿 = 𝑏𝑏0 + 𝐱𝐱 ′ 𝐛𝐛 + 𝐱𝐱 ′ 𝐁𝐁𝐁𝐁 + λ(𝑐𝑐0 + 𝐱𝐱 ′ 𝐜𝐜 + 𝐱𝐱 ′ 𝐂𝐂𝐂𝐂 − T)

The DMRCS Steps for Optimization

Myers et al proposed five steps that can help organize the optimization process, and
enhance a “structured decision that is defensible and rational” (Myers, Montgomery, &
Anderson-Cook, 2016). The steps which have been abbreviated by DMRCS are: Define,
Measure, Reduce, Combine and Select.
Define. This step clearly lays out the objective of the optimization process. The problem
to be solved, responses to be considered, factors involved in the design, and constraint ranges (if
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present) are all noted and clearly defined (Myers et al., 2016). This step makes sure that the
“correct problem is solved”. In multiple responses optimization, care is taken to ensure that
“decisions are represented with an appropriate response (Myers et al., 2016).
Measure. This step ensures that the data used for the analysis is of high quality.
Decisions based on the results of the optimization need to be “precisely and accurately measured
to allow fair and consistent comparisons between potential solutions” (Myers et al., 2016).
Reduce. It is important that too many responses are not to be included in the optimization
process, as the “trade-offs between responses increases as the number of facets considered
increases” (Myers et al., 2016). Another form of reduction is to “eliminate noncontending
solutions” from the optimization considerations.
Combine. Several methods can be used to combine different metrics into a form where
they can be easily compared. Tools such as “overlaying contours, constrained optimization, or
the desirability function approach with specific weights provide ways of eliminating portions of
the design space” help to make relevant conclusions from the optimization processes.
Select. The goal of the optimization process is to select a region of the optimized space
that meets the objectives of the study. Graphical tools play a big role in visualizing and
explaining results.
Using this structured approach can enhance the smoothness of implementation, and the quality of
results obtained (Myers et al., 2016).
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CHAPTER 3
METHODOLOGY
Data was generated to follow a study sponsored by a pharmaceutical organization
(NCT00281580, 2014). The study was a factorial design study for the treatment of Hypertension
I and II. The Primary outcome was change from baseline at 8 weeks in Seated Trough Cuff Mean
Diastolic Blood Pressure (DBP). Secondary outcome was change from baseline at 8 weeks in
Seated Trough Cuff Mean Systolic Blood Pressure. Drug A in doses of 0mg, 2.5mg, 5mg, and
10mg was given in combination with Drug B, in doses of 0mg, 20mg, 40mg and 80mg, for eight
weeks in patients with Hypertension stage I and II. The simstudy package in R software was
used to generate the data (Goldfeld, 2019). A total of 8000 observations were generated, 500
observations in each treatment group, with the following variables; identity number, dose of
Drug A, dose of Drug B, Baseline Diastolic Blood Pressure, End of Treatment Diastolic Blood
Pressure, Age, Gender, Edema and Headache. Baseline Diastolic Blood Pressure (DBP) was
generated to reflect a population like the study; i.e. those with hypertension I and II (that is, DBP
of ≥ 95 and ≤ 119), with an age range of 18 – 75 years. Gender distribution of 52% males, and
48% females in each treatment group, coded 1 for male and 2 for female. Table 2 shows the
mean and the standard deviation for each treatment group used to generate the baseline diastolic
blood pressure and the post baseline diastolic blood pressure (NCT00281580, 2014).
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Table 2: Parameters used for generating Data for the baseline and end of treatment diastolic
blood pressure
Group

Dose of Drug A

N

& Drug B

Mean (SD) for

Mean (SD) for

Baseline DP

Post Baseline DP

1

B0A0

500

107 (9.4)

101(9.4)

2

B20A0

500

107 (9)

94 (9)

3

B40A0

500

107 (10.1)

94 (10.1)

4

B80A0

500

107 (8.7)

93 (8.7)

5

B0A2.5

500

107 (9.9)

96 (9.9)

6

B0A5

500

107 (7.9)

94 (7.9)

7

B0A10

500

107 (7.1)

90 (7.1)

8

B20A2.5

500

107 (7.8)

89 (7.1)

9

B20A5

500

107 (6.5)

92 (6.5)

10

B20A10

500

107 (7)

88 (7)

11

B40A2.5

500

107 (8.2)

90 (8.2)

12

B40A5

500

107 (7.6)

90 (7.6)

13

B40A10

500

107 (7.9)

87 (7.9)

14

B80A2.5

500

107 (7.5)

91 (7.5)

15

B80A5

500

107 (8.5)

89 (8.5)

16

B80A10

500

107 (7.9)

87 (7.9)
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Table 3 shows summary results by treatment group combination: the mean of baseline
diastolic blood pressure, mean of end of treatment diastolic blood pressure, mean of change in
diastolic blood pressure, and their corresponding standard deviations.

These results were

produced using proc means in SAS.
Table 3: Summary of Generated Data
Group Dose

of N

Drug A &

Mean Baseline Mean End of

Mean change in DBP

DBP (SD)

(SD)

Drug B

Treatment DBP
(SD)

1

B0A0

500

106.95 (8.04)

101.01 (7.68)

5.94 (4.38)

2

B20A0

500

106.86 (7.98)

94.10 (7.90)

12.99 (4.36)

3

B40A0

500

107.12 (7.84)

93.99 (7.76)

13.13 (4.67)

4

B80A0

500

107.02 (7.85)

92.99 (7.92)

14.02 (4.18)

5

B0A2.5

500

106.85 (7.88)

96.03 (7.99)

10.82 (4.46)

6

B0A5

500

106.80 (7.55)

93.91 (7.62)

12.90 (4.06)

7

B0A10

500

106.89 (7.58)

89.99 (7.58)

16. 89 (3.74)

8

B20A2.5

500

107.09 (8.06)

88.59 (7.73)

18.50 (4.22)

9

B20A5

500

106.92 (7.83)

92.07 (7.27)

14.85 (10.91)

10

B20A10

500

106.91 (7.59)

88.02 (7.74)

18.90 (3.81)

11

B40A2.5

500

107.20 (7.74)

90.09 (7.89)

17.11 (3.92)

12

B40A5

500

107.14 (7.86)

90.10 (7.72)

17.04 (4.05)

13

B40A10

500

107.14 (7.6)

86.93 (7.61)

20.20 (3.95)

14

B80A2.5

500

106.77 (7.81)

91.14 (8.03)

15.66 (4.10)
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15

B80A5

500

106.87 (7.57)

89.16 (7.74)

17.71 (4.03)

16

B80A10

500

107.15 (7.55)

87.22 (7.64)

19.93 (4.11)

This dissertation uses generated diastolic blood pressure data and real adverse event
summary data of patients from the clinical trial (NCT00281580, 2014). Therefore, we compared
the means of the generated diastolic blood pressure data to the means of the actual diastolic
blood pressure data from the clinical trial (NCT00281580, 2014). Figures 1 and 2 are plots
comparing the mean blood pressure (baseline and post-baseline) from the original study with the
mean blood pressure (baseline and post-baseline) in the generated data.
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Figure 1: A Plot Comparing Baseline Mean Diastolic Blood Pressure
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Figure 2: A Plot Comparing Post-Baseline Mean Diastolic Blood Pressure
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Table 4 shows the number and percentages of edema (side effect) per treatment group at risk as
provided by the study (NCT00281580, 2014).
Table 4: Number and percentages of edema (side effect) per
treatment group at risk

Treatment Group

Peripheral Edema (%)

Placebo (B0A0)

0/46 (0)

B20A0

0/42 (0)

B40A0

1/130 (0.77)

B80A0

1/135 (0.74)

B0A2.5

1/50 (2)

B0A5

1/140 (0.71)

B0A10

23/129 (17.83)

B20A2.5

1/44 (2.27)

B20A5

2/46 (4.35)

B20A10

5/44 (11.36)

B40A2.5

0/47 (0)
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B40A5

2/143 (1.40)

B40A10

7/129 (5.43)

B80A2.5

1/48 (2.08)

B80A5

3/146 (2.05)

B80A10

16/142 (11.27)

The objective is to determine the optimum combination of doses and corresponding
confidence interval in a combined therapy of hypertension using drugs, Drug A and Drug B, in
the presence of a constraint; on edema (a common side effect).
Methods & Data Analysis.
The first approach was to perform a response surface procedure to obtain the
unconstrained optimum region or point of efficacy.
In response surface experiments, the relationship between the dependent and the independent
variables, x, is often expressed by a quadratic function (Lawson, 2010):
𝑓𝑓 (𝑥𝑥 ) = 𝛽𝛽0 + 𝒙𝒙′ 𝜷𝜷 + 𝒙𝒙′ 𝚩𝚩𝒙𝒙

Where;
𝑥𝑥1
𝑥𝑥2
𝒙𝒙 = � ⋮ � ,
𝑥𝑥𝑘𝑘

β
β1
⎡ 1 (11)
β
⎢ β
𝛃𝛃 = � 2 � , 𝚩𝚩 = ⎢ 2 (12)
⋮
⎢1 ⋮
β𝑘𝑘
⎣ 2β(1𝑘𝑘)

(3)
1
β
2 (12)

β(22)
⋮

1
β
2 (2𝑘𝑘)

⋯ 12β(1𝑘𝑘)
⎤
⋯ 12β(2𝑘𝑘) ⎥
⋱
⋮ ⎥⎥
⋯ β(𝑘𝑘𝑘𝑘) ⎦
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β0 is the intercept, x is a vector of design variables, β is the vector of the coefficients of the linear
terms in f(x) and B is a symmetric matrix containing functions of the coefficients of the quadratic
terms in f(x).
Let Yi be the dependent variable; the change in diastolic blood pressure, and 𝜖𝜖𝑖𝑖 are the

independent error terms which follow independent and identical normal distributions with mean
0 and equal variance 𝜎𝜎 2 . Then 𝑌𝑌𝑖𝑖 = 𝑓𝑓(𝑥𝑥 ) + 𝜖𝜖𝑖𝑖 and 𝑌𝑌𝑖𝑖 ~ 𝑁𝑁[𝑓𝑓(𝑥𝑥 ), 𝜎𝜎 2 ]
The likelihood function could then be expressed as:
𝑘𝑘

𝐿𝐿(𝑌𝑌𝑖𝑖 ) = � 𝑃𝑃(𝑌𝑌𝑖𝑖 )
𝑖𝑖=1

Where 𝑃𝑃(𝑌𝑌𝑖𝑖 ) is the normal density of 𝑌𝑌𝑖𝑖 which has mean f(x) and variance 𝜎𝜎 2 .
𝑘𝑘

ln 𝐿𝐿(𝑌𝑌𝑖𝑖 ) = � ln 𝑃𝑃(𝑌𝑌𝑖𝑖 )
𝑖𝑖=1

𝑘𝑘

= � 𝜀𝜀𝑖𝑖2
𝑖𝑖=1

𝑘𝑘

𝑘𝑘

𝑖𝑖=1

𝑗𝑗=1

2

= � �𝑦𝑦𝑖𝑖 − 𝛽𝛽0 − � 𝛽𝛽𝑗𝑗 𝑥𝑥𝑖𝑖𝑖𝑖 �

(4)

The optimum response of the response surface methodology occurs at the stationary
point. The stationary point can be expressed as:
1 −𝟏𝟏
� 𝐛𝐛
𝐱𝐱 𝐩𝐩 = − 𝐁𝐁
2
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which is derived by setting the derivative of equation (4) to 0.
The predicted response at the stationary point can be expressed as:
� 𝐱𝐱 𝐩𝐩
𝑦𝑦�𝑝𝑝 = 𝑏𝑏0 + 𝐱𝐱′𝐩𝐩 𝐛𝐛 + 𝐱𝐱′𝐩𝐩 𝐁𝐁

𝟏𝟏
� −𝟏𝟏 � 𝐁𝐁
� 𝐱𝐱 𝐩𝐩
= 𝑏𝑏0 + 𝐱𝐱 ′ 𝐩𝐩 𝐛𝐛 + �− 𝐛𝐛′ 𝐁𝐁
𝟐𝟐
= 𝑏𝑏0 +

1 ′
𝐱𝐱 𝐛𝐛
2 𝒑𝒑

The quadratic equation (3) can illustrate a variety of surfaces, such as ridges, hilltops,
valleys and saddle points (Lawson, 2010). Whether f(x) is a minimum or maximum is determined
� matrix. If the eigenvalues are positive, it is a maximum. If negative,
by the eigenvalues of the 𝐁𝐁

the point is a minimum. And if the signs are mixed (positive and negative), then the stationary
point would be a saddle point.
In order to fit the response surface model in SAS, one would need to employ the use of
the SAS Response Surface Regression Procedure (RSREG). To better understand the fitted
surface, a contour plot or a three-dimensional plot can be made. In the case of more than one or
more contour plots, it is useful to perform a canonical analysis, where the exact factor
coordinates of the optima can be determined. These can be determined by setting the derivates of
the equation which have been fitted to zero and finding the solutions (Lawson, 2010).
Data Analysis was done using SAS 9.4. The RSREG procedure was used to find the
optimum response region assuming a full quadratic response function. According to SAS, Proc
RSREG can also be used to test for lack of fit, test for the significance of individual factors,
analyze the canonical structure of the estimated response surface, compute the ridge of optimum
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response and predict new values of the response. The independent variables are the doses of
Drug A and B in combination therapy. The dependent variable is the change in Diastolic Blood
Pressure (DBP) from baseline to end of treatment after 8 weeks. The estimates of betas
(𝛽𝛽0 , 𝛽𝛽1 , 𝛽𝛽2 , 𝛽𝛽11 , 𝛽𝛽12 , 𝛽𝛽22 ) in the full quadratic model were obtained from fitting the regression
model using SAS PROC RSREG:

𝑦𝑦 = 𝛽𝛽0 + 𝛽𝛽1 𝑥𝑥1 + 𝛽𝛽2 𝑥𝑥2 + 𝛽𝛽11 𝑥𝑥12 + 𝛽𝛽22 𝑥𝑥22 + 𝛽𝛽12 𝑥𝑥1 𝑥𝑥2 + ε
Where y = the change in diastolic blood pressure
x1 = doses of Drug A
x2 = doses of Drug B
This assumes that the experimental errors are independent, normally distributed and have equal
variances.
The aim is to fit the model to the data, estimate parameters in the model, produce the
estimated Response Surface, and then find the values (perhaps a region) of dose variables for
which fitted model is optimum for some predicted response deemed clinical important.
The adverse effect (edema) was also modeled to have an idea of the region that produces
the highest probability of the occurrence of edema, in relation to the dose of Drug A and Drug B.
The presence of edema variable was coded as a binary variable (1 or 0) for each patient. The
presence of edema represented as 1 and 0 otherwise. This kind of data is known as the quantal
data, as it describes the “relationship between dose and the frequency of a particular outcome in
a given population” (World Health Organization, 2019b). Various models such as One-hit,
Gamma multi hit, Probit normal, and logistic, can be used on this type of data, depending on the
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distribution (World Health Organization, 2019b). Proc Logistic in SAS, with a Probit normal link
function, was used to produce predicted probabilities of edema occurrence at various dosage
combinations of Drug A and Drug B. The equation for the model is given as:

where:

𝑃𝑃 [𝑌𝑌 = 1] = Φ(𝛽𝛽0 + 𝛽𝛽1 𝑥𝑥1 + 𝛽𝛽2 𝑥𝑥2 + 𝛽𝛽11 𝑥𝑥12 + 𝛽𝛽22 𝑥𝑥22 + 𝛽𝛽12 𝑥𝑥1 𝑥𝑥2 )
Y = edema Status (1 or 0)
x1 = doses of Drug A
x2 = doses of Drug B
According to Myers et al, “a relatively straightforward approach to optimizing several

responses that works well when there are only a few variables is to overlay the contour plots”
(Myers et al., 2016). This can help the experimenter to “visually examine the contour plot for
determining appropriate operating conditions and select a region that is most desirable given
other practical conditions” (Myers et al., 2016). The Response Surface Regression (RSREG)
Procedure was used to overlay the contour plots of both the change in diastolic blood pressure,
and the probability of edema occurrence. The overlaid contours can easily show that region of
efficacy at a minimal risk of edema occurring. Different levels of efficacy can be visualized at
several probability levels of edema occurring, based on the dose of Drug A and Dose B.
Another method of optimization is the Constrained Optimization. “Constrained
Optimization is a set of methods designed to efficiently and systematically find the best solution
to a problem characterized by a number of potential solutions in the presence of identified
constraints” (Crown et al., 2017). To achieve this, an objective function is maximized or
minimized. The objective function represents the “measure of interest to the decision maker
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which is subject to constraints that restrict the decision maker’s freedom of action” (Crown et al.,
2017). A constrained optimization problem is made up of the objective function(s), decision
variable(s) and its constraint(s) (Crown et al., 2017).
“The Objective function is the function of the decision variables which needs to be
maximized or minimized. The decision variables are mathematical representation of the
constituents of the system for which decisions are being taken to improve the value of the
objective function value of the objective function. The constraints are the restrictions placed on
the decision variables” (Crown et al., 2017).
The objective of the constrained optimization is to maximize f (x, y) given a constraint
function; g (x, y) ≥ 0. In this study we maximized the objective function:
𝑦𝑦 = 𝛽𝛽0 + 𝛽𝛽1 𝑥𝑥1 + 𝛽𝛽2 𝑥𝑥2 + 𝛽𝛽11 𝑥𝑥12 + 𝛽𝛽22 𝑥𝑥22 + 𝛽𝛽12 𝑥𝑥1 𝑥𝑥2 + ε

Subject to:

Φ(𝛽𝛽0 + 𝛽𝛽1 𝑥𝑥1 + 𝛽𝛽2 𝑥𝑥2 + 𝛽𝛽11 𝑥𝑥12 + 𝛽𝛽22 𝑥𝑥22 + 𝛽𝛽12 𝑥𝑥1 𝑥𝑥2 ) ≤ desired target probability of
edema occurrence.

This assumes that the experimental errors (ε) are independent, normally distributed and have

equal variances.

The RSREG procedure in SAS for searching multiple response conditions was used to
perform the constrained optimization, using different target probability of edema occurrence, and
finding constrained optimal values.
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CHAPTER 4
RESULTS
The Response Surface Methodology (RSM) was performed using Response Surface
Regression (RSREG) Procedure in SAS. The unconstrained total model was statistically
significant at 0.05 significant level (<0.001). As shown in Table 5, the predicted change in
baseline diastolic pressure increases as the dose of Drug A and/or Drug B increase respectively.
The lack of fit also revealed a significant result, as expected due to the large sample size and an
R-square of 38.4%.
Table 5: ANOVA Summary, RSM Analysis
Response

15.437

Mean
Root MSE

4.217

R-Square

0.3838

CV

27.32

Regression

DF

Type I SS

R-Square

F value

Prob

Linear

2

71507

0.2442

1409.67

<.0001

Quadratic

2

17148

0.0586

338.05

<.0001

Cross Product

1

1392.04

0.0048

54.88

<.0001

Total Regress

5

90047

0.3075

710.06

<.0001

Residual

DF

SS

MS

F value

Prob

Lack of fit

10

14680

1468.04

62.32

<.0001
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Pure error

7984

188073

23.57

Total error

7994

202753

25.36

Parameter

DF

Estimate

SD

T value

Prob

Intercept

1

7.827

0.1623

48.24

<.0001

X1 (Dose B)

1

0.2327

0.0072

32.28

<.0001

X2 (Dose A)

1

1.2627

0.0577

21.91

<.0001

X1*X1

1

-0.001950

0.00007940

-24.56

<.0001

X1*X2

1

-0.003814

0.000515

-7.41

<.0001

X2*X2

1

-0.043344

0.005082

-8.53

<.0001

Factor

DF

SS

MS

F

Prob

X1

3

37439

12480

492.04

<.0001

X2

3

54000

18000

709.69

<.0001

Results also showed a stationary maximum point, with a predicted value at 21.24mmhg.
Figure 1 and Figure 2 represents the contour plots and the surface graph respectively. Both
figures show different values of the change in diastolic blood pressure at different combinations
of Drug A and Drug B. From the contour plots and surface graph, one can deduce that the
optimal point of efficacy is a change (reduction) in diastolic blood pressure from baseline to 8
weeks of about 21mmhg. This optimal point of efficacy was associated with about 12mg of Drug
A and 48mg of Drug B (which is close to marketed 10mg of Drug A and 40mg of Drug B).
Table 6 shows the treatment groups, and the corresponding predicted change in diastolic blood
pressure, with their confidence intervals.
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Table 6: Values of predicted change in diastolic pressure with confidence Intervals
Group

Dose A

Dose B

Predicted

Confidence

Change in DBP Interval (mmHg)
(mmHg)
1

0

0

7.82

(-2.05, 17.70)

2

0

20

11.70

(1.83, 21.58)

3

0

40

14.02

(4.14, 23.89)

4

0

80

13.96

(4.08, 23.84)

5

2.5

0

10.71

(0.84, 20.59)

6

5

0

13.06

(3.19, 22.93)

7

10

0

16.13

(6.25, 26.01)

8

2.5

20

14.40

(4.53, 24.27)

9

5

20

16.55

(6.68, 26.43)

10

10

20

19.24

(9.57, 29.12)

11

2.5

40

16.52

(6.65, 26.40)

12

5

40

18.48

(8.61, 28.36)

13

10

40

20.79

(10.92, 30.66)

14

2.5

80

16.08

(6.21, 25.96)

15

5

80

17.67

(7.79, 27.54)

16

10

80

19.42

(13.24, 25.59)
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Figure 3: Response Contour Plot for the Change in Diastolic Blood Pressure.

Figure 4: Response Surface Graph for Change in Diastolic Blood Pressure.
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Table 7 summarizes results from the Probit Model for the probability of edema
occurrence by the dose combinations of Drug A and Drug B. Results showed that a one unit (mg)
change in the dose of Drug A increases the probability of edema status by 0.11%, a one unit (mg)
change in the dose of Drug B decreases the probability of edema status by 0.0159%, and a one
unit (mg) change in the combination of Drug A and B decreases the probability of edema by
0.00024%.
Table 7: Probit Model Summary Results
Parameter

DF Estimate

Standard

Wald

Error

Chi-Square

Pr > ChiSq

Intercept

1

-2.3912

0.1195

400.69

<.0001

DoseA

1

0.1099

0.0424

7.4662

0.0063

DoseB

1

-0.0159

0.00387

16.9421

<.0001

DoseA*DoseB 1

-0.00024

0.000252

0.9043

0.3416

DoseA*DoseA 1

0.00297

0.00322

0.8538

0.3555

DoseB*DoseB

0.000194

0.000041

22.6960

<.0001

1

Table 8 shows a summary of results from the probit normal model, showing the predicted
probability of edema per dose combination, the difference in predicted probabilities (subtracted
from probability of edema when its placebo) and the predicted optimal value of change in blood
pressure. The point of minimum risk is at dose of Drug A 2.5mg and Drug B 40mg (if
considering the combination). The region of minimal edema incidence lies around dosage
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combination of Drug A 2.5mg and Drug B 20 – 40mg. The probability of edema reduces as the
dosage of Drug B increases in the combination with Drug A.
Table 8: Summary Results from Probit Regression showing Predicted Probability of Edema,
difference from Placebo and the Predicted Change in Diastolic Pressure (CDBP) Optimal
Value.
Group Dose of Predicted
Prob
Drug A Event (Edema)
& Drug
B
1
B0A0
0.0083(0.83%)

of Difference of Predicted Predicted Value
Prob (from Placebo)
(mmHg) from RSREG
7.82

2

B20A0

0.0042(0.42%)

-0.004

11.70

3

B40A0

0.0033(0.33%)

-0.005

14.02

4

B80A0

0.0076 (0.76%)

-0.0007

13.96

5

B0A2.5

0.018 (1.8%)

0.0097

10.71

6

B0A5

0.039 (3.9%)

0.031

13.06

7

B0A10

0.159 (15.9%)

0.151

16.13

8

B20A2.5 0.009 (0.9%)

0.0007

14.40

9

B20A5

0.021 (2.1%)

0.0127

16.55

10

B20A10

0.109 (10.9%)

0.1007

19.24

11

B40A2.5 0.0072 (0.7%)

-0.0011

16.52

12

B40A5

0.016 (1.6%)

0.0077

18.48

13

B40A10

0.078 (7.8%)

0.0697

20.79

14

B80A2.5 0.015 (1.5%)

0.0067

16.08

15

B80A5

0.0207

17.67

0.029 (2.9%)
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16

B80A10

0.111 (11.1%)

0.1027

19.42

Figure 5 shows the response surface plot showing the highest probability of edema at
15.3%, associated with Drug A 10mg and Drug B 0mg.

It is important to note that the

probability reduced by 5% (10.9%) when Drug B 20mg was added to the combination.
Figure 5: A Surface Plot showing the Probability of Edema occurrence by Doses.

An overlaid contour plot is a good way of visualizing both responses and selecting a
region of interest e.g. where the probability of edema is lowest. Figure 4 is an overlaid contour
plot showing the estimated probabilities of edema occurring at different doses of Drug A and
Drug B combinations. One can visually observe that the region of zero probability of edema
occurring is around 2.5mg of Drug A and 20 – 40mg of Drug B, and slightly above a change in
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diastolic blood pressure of 15mmHg. There will be a 20mmHg efficacy achieved with 10mg of
Drug A and 50mg of Drug B, but with a 10% predicted probability of edema occurrence.
Figure 6: An Overlaid Contour Plot for the Change in Diastolic Blood Pressure and the
Probability of Edema Occurrence, at different combinations of Drug A and Drug B.

Further analysis involved finding the constrained optimal point of efficacy at different
targets of predicted probability. Table 9 shows results for respective dosage combinations of
Drug A and Drug B at different levels of predicted probability of edema.

43
Table 9: Sensitivity Analysis showing respective dosage combinations at different targets of
predicted probability of edema
Target Probability of DoseA

DoseB

CDBP Optimal Value

Edema Incidence (t)
0% < t ≤ 1%

4

56

18.25

1% < t ≤ 2%

5

55

18.91

2% < t ≤ 3%

6

54

19.49

3% < t ≤ 4%

7

53

19.98

4% < t ≤ 5%

7

53

19.98

5% < t ≤ 10%

10

50

20.98

44
CHAPTER 5
DISCUSSION AND CONCLUSION
Response Surface Methodology (RSM) is a “collection of statistical and mathematical
techniques useful for developing, improving, and optimizing processes” (Myers et al., 2016).
This method has been useful in different organization and industries, from agriculture to health
care, in the design and improvement of new products (Myers et al., 2016). The aim of this
project was to use these methods to optimize combination drug therapy among hypertensive
patients, while taking into consideration common side effects that occur among those being
treated with these drugs.
This study focused on two drugs commonly combined for the treatment of hypertensive I
and II patients. Design and data parameters were similar to the study conducted by a
pharmaceutical industry: Factorial Design Study for the Treatment of Hypertension (Clinical trial
identification number: NCT00281580). Results from the first stage of this study revealed the
optimum point of efficacious response. The optimum change in blood pressure from baseline
diastolic blood pressure to end – of – treatment blood pressure, after 8 weeks, was estimated as
21mmhg. This point of optimal response was associated with a stationary point of 10mg of Drug
A and 40mg of Drug B.
The other part of the study was to formulate a clinically reasonable safety constraint to be
added to the model. The objective was to optimize the combination drug therapy while
constraining for the probability of edema incidence. The point of minimum risk occurs when
dose of Drug A is 2.5mg and dose of Drug B is 20mg (if considering the combination). While
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this might have occurred for the adverse effect Edema, it is important to note that it might not
apply to other adverse effects.
The optimal responses for the unconstrained and the constrained models should not be
taken and interpreted as exact, as it could lead to some misleading conclusions. The stationary
point only gives a suggestion as to the region of optimal response. Standard errors and
confidence regions around the stationary point should also be taken into consideration.
In clinical practice, the clinician is mostly concerned about the efficacy of the drug or
therapy, but it also advisable not to ignore the possibility of adverse effects (Myers et al., 2016).
Monotherapy or combined therapy in hypertension are done to suite the physical and biological
qualities of patients. Different patients react to drugs differently. Most often, it is the duty of the
physician to advise on the best drugs or therapy for a patient. The response to drug or therapy for
an individual depends on several factors such as age, sex, race, genetics and hereditary factors.
This study was not able to consider these factors in the analysis, which is one of its limitations.
Also, though Response Surface Methodology (RSM) have been applied in many disciplines,
constraint optimization methods are still very novel in its application to health and clinical
therapy. Application of this method will require formulation of constraints that suites the disease
of interest, and that is also clinically explainable.
Public Health Implications
“Patient safety is an essential principle of healthcare” (Al-Saadoon, 2015).

The

effectiveness of drugs and the occurrence of unexpected, unwanted and unpredictable adverse
drug reactions continue to be a serious public health problem. These have been noted to be one
of the major causes of hospitalizations in many countries of the world (Kollek, van Aken,
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Feuerstein, & Schmedders, 2006). Adverse effects could be associated with any phase of
healthcare; Practice, Products, Procedures or Provision (Al-Saadoon, 2015). Several measures,
such as pharmacogenetics and pharmacovigilance are being put in place, to ensure drugs have
required efficacy with less occurrence of adverse effects. This is to ensure that major public
health programs are supported through “providing reliable, balanced information for the effective
assessment of the risk-benefit profile of medicines” (World Health Organization, 2019a). The
aims of the WHO Pharmacovigilance are to: (i) improve patient care and safety in relation to the
use of medicines and all medical and paramedical interventions; (ii) improve public health and
safety in relation to the use of medicines; (iii) detect problems related to the use of medicines and
communicate the findings in a timely manner; (iv) contribute to the assessment of benefit, harm,
effectiveness and risk of medicines, leading to the prevention of harm and maximization of
benefit; (v) encourage the safe, rational and more effective (including cost-effective) use of
medicines; and (vi) promote understanding, education and clinical training in pharmacovigilance
and its effective communication to the public (World Health Organization, 2019a).
In the United states, the Center for Drug Evaluation and Research (CDER), branch of the
Food and Drug administration (FDA) “performs an essential public health task by making sure
that safe and effective drugs are available to improve the health of the people in the United
States” (Food and Drug Administration, 2019). CDER ensure that drugs information, safety and
availability are regularly updated. The Drug safety communications provides relevant and
updated information to the public in the English and Spanish Language. Every year, there is a
new and updated release of information. CDER also controls the drug development and review
process, regulatory science research and education, drug approvals and databases, and guidance,
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compliance/regulatory information. They also prepare and respond to natural disasters, nuclear
and chemical attacks (Food and Drug Administration, 2019).
Policy Implementation
The World Health Organization has established policies to control the safety and
utilization of drugs worldwide. One of those initiations is the Quality Assurance and Safety of
Medicines (QSM). The QSM issues guidelines as regards to the nomenclature, quality norms and
standards, drug safety and regulatory information exchange, prequalification of priority
medicines, and harmonization of medicine regulations (World Health Organization, 2019c). The
WHO also established the Collaborating Center for International Drug Monitoring to help
maintain database for reports of adverse reactions from member states (Al-Saadoon, 2015). In
the United States, the FDA also acts a governing and regulatory body. They provide the
guidance, compliance and regulatory information to ensure proper control of production and use
of drugs and devices. To provide evidence of effectiveness of new drugs and devices, the US.
Department of Health and Human Services, Food and Drug Administration, Center for Drug
Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)
issued a document to guide the industry in the production of new drugs, biologics or devices. In
April 2019, the FDA also issued a compliance policy for combination product post-marketing
safety.
Suggestions for Future Research
Constrained optimization methods have had very few applications in the health sector,
and in drug therapy. Further studies are advised on other disease of interest, and more simpler
measures will help to enhance improvement in this area. There are also few software supports,
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especially in the multi-response situations. There is need for more development of reliable
software support systems to implement methodologies and perform analysis. There should also
be modifications in the multi-response technique to allow the inclusion of block effect in the
model (Khuri, 2017). There is need for research and development for non-parametric techniques;
model-free techniques (Khuri, 2017).
The methods used in this research were applied to a generated data set to mimic data from a
Phase III clinical trial of doses of two drugs used in combination to treat hypertensive I and II
patients. In practice, a Phase II clinical trial would be conducted, and the methods used to
estimate doses of the two drugs that would be predicted to provide maximum efficacy while
constraining important adverse events to an acceptable clinical level. These doses would then be
used in a Phase III clinical trial for confirmation.
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